bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Up 17.3% in July

bioAffinity Technologies, Inc. (NASDAQ:BIAF) saw a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 708,000 shares, a growth of 17.3% from the July 15th total of 603,700 shares. Approximately 12.6% of the company’s shares are short sold. Based on an average daily trading volume, of 119,800 shares, the days-to-cover ratio is presently 5.9 days.

bioAffinity Technologies Stock Up 4.6 %

Shares of BIAF stock traded up $0.08 during trading on Friday, reaching $1.81. The company’s stock had a trading volume of 45,748 shares, compared to its average volume of 148,957. bioAffinity Technologies has a one year low of $0.95 and a one year high of $3.62. The business has a fifty day moving average price of $2.17 and a 200-day moving average price of $2.14. The company has a market cap of $21.10 million, a price-to-earnings ratio of -1.95 and a beta of 2.95. The company has a quick ratio of 2.21, a current ratio of 2.22 and a debt-to-equity ratio of 0.14.

bioAffinity Technologies (NASDAQ:BIAF) last released its earnings results on Wednesday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter. The company had revenue of $2.41 million during the quarter. bioAffinity Technologies had a negative net margin of 171.43% and a negative return on equity of 134.34%.

Analysts Set New Price Targets

Separately, Maxim Group began coverage on bioAffinity Technologies in a research note on Tuesday, July 23rd. They set a “buy” rating and a $6.00 price objective on the stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in bioAffinity Technologies stock. Ground Swell Capital LLC acquired a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned about 0.20% of bioAffinity Technologies as of its most recent SEC filing. 1.64% of the stock is currently owned by hedge funds and other institutional investors.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.